News

iTeos Therapeutics regains rights to IDO1 inhibitor

Country
Belgium

Belgium-based iTeos Therapeutics SA has regained rights to an early-stage cancer drug from Pfizer Inc which was being investigated in a Phase 1 trial as a potential single agent for treating patients with malignant gliomas.

BioNTech raises $270 million for cancer vaccines

Country
Germany

BioNTech AG, Europe’s largest privately-held biotech company, has raised $270 million in a Series A financing round to advance a portfolio of oncology drugs tailored to individual cancers. The round was led by the Redmile Group and joined by the Struengmann Family Office, a founding investor.

Spark offers outcomes-based rebates for gene therapy

Country
United States

Spark Therapeutics Inc has set the price per patient of its new gene therapy for retinal dystrophy at $850,000 but at the same time opened negotiations with leading US insurers to link payments with the success of the treatment.

BI increases size of corporate venture fund

Country
Germany

Boehringer Ingelheim GmbH has more than doubled the size of its corporate venture capital fund to €250 million in order to take advantage of new investment opportunities in start-up companies developing cell and gene therapies and products for infectious disease and cancer.

TiGenix tightens allogeneic focus

Country
Belgium

Following a positive opinion in Europe for its cell therapy for fistulas in Crohn’s disease, TiGenix NV has tightened its therapeutic focus to concentrate on allogeneic therapies and in particular, on inflammatory conditions associated with immune-mediated diseases.

ISA and Regeneron to co-develop combination therapy

Country
Netherlands

Netherlands-based ISA Pharmaceuticals BV has secured its first industrial collaboration for a product developed from its synthetic long-peptide portfolio, a deal which both validates the technology and illustrates the trend in immuno-oncology towards the development of combination therapies.

Roche to acquire Ignyta for $1.7 billion

Country
Switzerland

Roche has reached an agreement to acquire California, US- based Ignyta Inc for $1.7 billion, a company with small molecule therapies targeting kinases which have been activated by gene fusions – a class of oncogenes associated with both blood cancers and solid tumours.

Investors support Orchard Therapeutics’ gene therapies

Orchard Therapeutics Ltd has completed an oversubscribed $110 million Series B financing round to support its pipeline of gene therapies which is led by a clinical-stage product for the inherited disorder, adenosine deaminase severe combined immunodeficiency (ADA-SCID).

Alzheimer’s trial fails early test

Country
United States

A Phase 2 study of a new antibody treatment for Alzheimer’s disease has failed to meet its primary endpoint using an adaptive trial design that was intended to show efficacy at 12 months.  Biogen Inc and Eisai Co Ltd said the blinded study will continue until the second half of 2018.

FDA approves new gene therapy

Country
United States

The first gene therapy for patients with an inherited retinal disease was authorised by the US Food and Drug Administration on 19 December, bringing the number of approved gene therapies in the US up to three. Luxturna (voretigene neparvovec-rzyl), was developed by Spark Therapeutics Inc.